207 related articles for article (PubMed ID: 24434152)
1. PTEN overexpression improves cisplatin-resistance of human ovarian cancer cells through upregulating KRT10 expression.
Wu H; Wang K; Liu W; Hao Q
Biochem Biophys Res Commun; 2014 Feb; 444(2):141-6. PubMed ID: 24434152
[TBL] [Abstract][Full Text] [Related]
2. Recombinant adenovirus-mediated overexpression of PTEN and KRT10 improves cisplatin resistance of ovarian cancer in vitro and in vivo.
Wu H; Wang K; Liu W; Hao Q
Genet Mol Res; 2015 Jun; 14(2):6591-7. PubMed ID: 26125866
[TBL] [Abstract][Full Text] [Related]
3. [Reversal of drug resistance in human ovarian cancer cells by wild-type PTEN gene and its mechanisms].
Wu HJ; Wu HT; Weng DH; Xing H; Lu YP; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):612-6. PubMed ID: 17983517
[TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug resistance and inhibition of phosphorylation of AKT in human ovarian cancer cell line by wild-type PTEN gene.
Wu H; Weng D; Xing H
J Huazhong Univ Sci Technolog Med Sci; 2007 Dec; 27(6):713-6. PubMed ID: 18231751
[TBL] [Abstract][Full Text] [Related]
5. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms.
Wu H; Cao Y; Weng D; Xing H; Song X; Zhou J; Xu G; Lu Y; Wang S; Ma D
Cancer Lett; 2008 Nov; 271(2):260-71. PubMed ID: 18657898
[TBL] [Abstract][Full Text] [Related]
6. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
Chock KL; Allison JM; Shimizu Y; ElShamy WM
Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
[TBL] [Abstract][Full Text] [Related]
7. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
8. [Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines].
Li NW; Wang HJ; Yang LY; Jia XB; Chen C; Wang X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):865-70. PubMed ID: 24490491
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
10. Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.
Wang H; Fan L; Xia X; Rao Y; Ma Q; Yang J; Lu Y; Wang C; Ma D; Huang X
Int J Gynecol Cancer; 2012 Jun; 22(5):755-61. PubMed ID: 22635028
[TBL] [Abstract][Full Text] [Related]
11. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells.
Fu X; Tian J; Zhang L; Chen Y; Hao Q
FEBS Lett; 2012 May; 586(9):1279-86. PubMed ID: 22465665
[TBL] [Abstract][Full Text] [Related]
12. STAT3 regulated
Jin P; Liu Y; Wang R
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 30061175
[TBL] [Abstract][Full Text] [Related]
13. Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis.
Liu S; Fang Y; Shen H; Xu W; Li H
Acta Biochim Biophys Sin (Shanghai); 2013 Sep; 45(9):756-62. PubMed ID: 23824073
[TBL] [Abstract][Full Text] [Related]
14. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
15. Berberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through miR-93/PTEN/Akt Signaling Pathway.
Chen Q; Qin R; Fang Y; Li H
Cell Physiol Biochem; 2015; 36(3):956-65. PubMed ID: 26087719
[TBL] [Abstract][Full Text] [Related]
16. Phosphatase and Tensin Homolog Is a Potential Target for Ovarian Cancer Sensitization to Cytotoxic Agents.
McCormick A; Earp E; Leeson C; Dixon M; O'Donnell R; Kaufmann A; Edmondson RJ
Int J Gynecol Cancer; 2016 May; 26(4):632-9. PubMed ID: 26905328
[TBL] [Abstract][Full Text] [Related]
17. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
18. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance.
Singh M; Chaudhry P; Fabi F; Asselin E
BMC Cancer; 2013 May; 13():233. PubMed ID: 23663432
[TBL] [Abstract][Full Text] [Related]
20. L-Tetrahydropalmatine enhances the sensitivity of human ovarian cancer cells to cisplatin via microRNA-93/PTEN/Akt cascade.
Gong J; Xing C; Wang LY; Xie SS; Xiong WD
J BUON; 2019; 24(2):701-708. PubMed ID: 31128026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]